Karyopharm Therapeutics Inc (KPTI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Karyopharm Therapeutics Inc (KPTI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH259175D
  • |
  • Pages: 40
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Karyopharm Therapeutics Inc (Karyopharm Therapeutics) is a clinical-stage pharmaceutical company that focuses on the discovery and development of drugs for the treatment of cancer and other diseases. The company's lead product candidate, Selinexor, a selective inhibitor of nuclear export XPO1 antagonist indicated for the treatment of various hematological and solid tumor malignancies including multiple myeloma, acute myeloid leukemia, diffuse large B-cell lymphoma, liposarcoma, glioblastoma and gynecological malignancies. Its pipeline of SINE compounds also intended for the treatment of viral indications, wound-healing, neurological disorders, inflammation and autoimmune diseases. Karyopharm Therapeutics is headquartered in Newton, Massachusetts, the US.

Karyopharm Therapeutics Inc (KPTI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Karyopharm Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Karyopharm Therapeutics Raises US$67.2 Million In Series B Venture Financing 12

Karyopharm Therapeutics Secures US$10 Million In Series A2 Financing Round 13

Partnerships 14

Veristat Enters into Agreement with Karyopharm Therapeutics 14

Karyopharm Therapeutics Enters Into Co-Development Agreement With Rega Institute For Medical Research 15

Equity Offering 16

Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 16

Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 17

Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 18

Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For US$125 Million 21

Karyopharm Therapeutics Inc-Key Competitors 23

Key Employees 24

Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

Nov 07, 2016: Karyopharm Reports Third Quarter 2016 Financial Results and Highlights Recent Progress 26

Aug 04, 2016: Karyopharm Reports Second Quarter 2016 Financial Results and Highlights Recent Progress 28

May 09, 2016: Karyopharm Reports First Quarter 2016 Financial Results and Highlights Recent Progress 30

Mar 14, 2016: Karyopharm Reports Fourth Quarter and Full Year 2015 Financial Results and Highlights Recent Progress 32

Corporate Communications 34

Apr 03, 2017: Karyopharm Announces Management Change 34

Product News 35

06/10/2016: Karyopharm Therapeutics Presents data on KPT-8602 at 2016 European Hematology Association Annual Meeting 35

03/31/2016: Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus 36

03/16/2016: Karyopharm to Present Data on Oncology drug KPT-8602 at the 2016 American Association for Cancer Research Annual Meeting 37

Clinical Trials 38

Dec 15, 2016: Karyopharm and Collaborators Awarded Grant for ALS Research 38

Apr 20, 2016: Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1) Inhibition in the Treatment of Traumatic Brain Injury 39

Appendix 40

Methodology 40

About GlobalData 40

Contact Us 40

Disclaimer 40

List of Figures

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Karyopharm Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10

List of Tables

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 1

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Karyopharm Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 9

Karyopharm Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 10

Karyopharm Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11

Karyopharm Therapeutics Raises US$67.2 Million In Series B Venture Financing 12

Karyopharm Therapeutics Secures US$10 Million In Series A2 Financing Round 13

Veristat Enters into Agreement with Karyopharm Therapeutics 14

Karyopharm Therapeutics Enters Into Co-Development Agreement With Rega Institute For Medical Research 15

Karyopharm Therapeutics to Raise up to USD50 Million in Public Offering of Shares 16

Karyopharm Therapeutics Raises USD97.4 Million in Public Offering of Shares 17

Karyopharm Therapeutics Raises USD120.88 Million in Public Offering of Shares 18

Karyopharm Therapeutics Completes Underwriters Exercise Of Full Over-Allotment Option Of IPO For US$125 Million 21

Karyopharm Therapeutics Inc, Key Competitors 23

Karyopharm Therapeutics Inc, Key Employees 24

Karyopharm Therapeutics Inc, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Karyopharm Therapeutics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com